Jon CohenScience’s COVID-19 reporting is supported by the Pulitzer Center and the Heising-Simons Foundation.A second company has provided preliminary evidence that proactively infusing healthy people with monoclonal antibodies against SARS-CoV-2 prevents them from developing noticeable symptoms of COVID-19 if they are exposed to the coronavirus.
In a press release today, Regeneron revealed that when it gave a cocktail of two of those antibodies to 186 people living in a house with someone who had COVID-19, none developed symptomatic disease.The trial is ongoing, and the results have not yet posted as a preprint, let alone been published in a peer-reviewed journal.